Clinical parameters to predict response to interferon in relapsing multiple sclerosis

Neuroepidemiology

Volumn 31, Issue 3, 2008, Pages 150-156

  Fromont, A ^a   Debouverie, M ^b   Le Teuff, G ^a   Quantin, C ^a   Binquet, C ^a   Moreau, T ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Interferon responders; Multiple sclerosis, relapsing remitting

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; DATA BASE; DISABILITY SEVERITY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PARAMETER; PROGNOSIS; TREATMENT RESPONSE;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FRANCE; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PATIENT SELECTION; RECURRENCE; REGRESSION ANALYSIS;

EID: 49849101960     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151524     Document Type: Article

References (31)

1. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993;43:655-661.
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
4. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, Rice GP: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
5. Limmroth V, Kalski G, Richter A, et al: Quality assessment in multiple sclerosis therapy - the QUASIMS survey. 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Mult Scler 2003;P140.
6. Rio J, Tintoré M, Nos C, Téllez N, Falip M, Montalban X: Interferon beta in RRMS: an observational study. 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Mult Scler 2003;P506.
7. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P: Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003;9:451-457.
8. Roullet E, Pez D, Le Canuet P, et al: Application of different criteria for clinical response to beta interferon in relapsing remitting MS. Neurology 2003;suppl 1:A168.
9. Villoslada P, Oksenberg J, Rio J, Montalban X: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004;62:1653.
10. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
11. Multiple sclerosis: consensus conference organized by the French Federation for Neurology, 7-8 June 2001. Rev Neurol (Paris) 2001;157:902-1192.
12. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ: EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-676.
13. Moreau T, Gras P: Le réseau bourguignon de la sclérose en plaques. Rev Neurol 2003;suppl 3:2S75.
14. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782.
16. Weinshenker BG, Ebers GC: The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.
17. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL: Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122:552-568.
18. Abrahamowicz M, du Berger R, Grover SA: Flexible modeling of the effects of serum cholesterol on coronary heart disease mortality. Am J Epidemiol 1997;145:714-729.
19. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M: Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998;51:765-772.
20. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, Livrea P: Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300-306.
21. Raine CS, McFarland HF, Tourtellotte WW (eds): Multiple Sclerosis: Clinical and Pathogenetic Basis. London, Chapman & Hall Medical, 1997.
22. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP: Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler 2006;12:281-286.
23. Lublin FD, Baier M, Cutter G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532.
24. O'Rourke K, Walsh C, Antonelli G, Hutchinson M: Predicting beta interferon failure in relapsing remitting multiple sclerosis. Mult Scler 2007;13:336-342.
25. Confavreux C, Vukusic S: Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257-266.
26. Moreau T, Confavreux C: Can the prognosis of multiple sclerosis be predicted? Pathol Biol (Paris) 2000;48:132-138.
27. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, Montalban X: Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52:400-406.
28. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C: Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127:1353-1360.
29. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A: Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
30. McFarland HF, Barkhof F, Antel J, Miller DH: The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002;8:40-51.
31. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, Caillier S, Stillman A, Hauser SL, Montalban X, Oksenberg JR: Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003;4:147-152.